BDBM160931 US9107954, 1

SMILES CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC2CC2)c56)cc1

InChI Key InChIKey=BAVVASQPMQMZER-XJSRWQIGSA-N

Data  4 KI  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 160931   

TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataKi:  51.8nMAssay Description:A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule w...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataKi:  52nMAssay Description:Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO cells after 1 hrMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 5(Macaca fascicularis)
Virginia Commonwealth University

Curated by ChEMBL
LigandPNGBDBM160931(US9107954, 1)
Affinity DataKi:  239nMAssay Description:Displacement of [125I]-MIP-1alpha from CCR5 in rhesus monkey Chem-1 cell membranes after 120 mins by liquid scintillation counting analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataKi:  239nMAssay Description:Afterwards, the pharmacological profile of bivalent ligand 1 at the chemokine receptor CCR5 was characterized similarly. The competitive radioligand ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataIC50:  40nMAssay Description:Antagonist activity at human mu opioid receptor expressed in Gqi5 transfected CHO cells assessed as inhibition of DAMGO-stimulated Ca2+ influx preinc...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataIC50:  126nMAssay Description:Antagonist activity at CCR5 in Gqi5 transfected human MOLT4 cells assessed as inhibition of RANTES-stimulated Ca2+ influx preincubated for 15 mins fo...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataIC50:  40nMAssay Description:As Ca2+ flux is associated with the activation of the MOR, the functional activity of bivalent ligand 1, monovalent ligand 2, and naltrexone was then...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC-C chemokine receptor type 5(Homo sapiens (Human))
Virginia Commonwealth University

US Patent
LigandPNGBDBM160931(US9107954, 1)
Affinity DataIC50:  126nMAssay Description:Then the Ca2+ functional activity of bivalent ligand 1 was evaluated in the Gqi5 transfected CCR5-MOLT-4 cells as described in the literature.3 As ex...More data for this Ligand-Target Pair
In DepthDetails US Patent